JPH0555509B2 - - Google Patents
Info
- Publication number
- JPH0555509B2 JPH0555509B2 JP8848464A JP4846488A JPH0555509B2 JP H0555509 B2 JPH0555509 B2 JP H0555509B2 JP 8848464 A JP8848464 A JP 8848464A JP 4846488 A JP4846488 A JP 4846488A JP H0555509 B2 JPH0555509 B2 JP H0555509B2
- Authority
- JP
- Japan
- Prior art keywords
- benzothiepino
- pyridazin
- tetrahydro
- chlorophenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 hydroxy, amino Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 61
- 238000002844 melting Methods 0.000 description 51
- 230000008018 melting Effects 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000000034 method Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000000354 decomposition reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 7
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002249 anxiolytic agent Substances 0.000 description 6
- GLFHMYMOGBMFKJ-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCSC=2C3=CC(Cl)=CC=2)C3=N1 GLFHMYMOGBMFKJ-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- LEJAYRGELPEHFV-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCSC=2C3=CC(Cl)=CC=2)C3=N1 LEJAYRGELPEHFV-UHFFFAOYSA-N 0.000 description 4
- IIDYJQBIULBPTJ-UHFFFAOYSA-N 2-(4-bromophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 IIDYJQBIULBPTJ-UHFFFAOYSA-N 0.000 description 4
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 4
- 229940067157 phenylhydrazine Drugs 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QKMNPUHPWJFRFL-UHFFFAOYSA-N 10-fluoro-2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCSC=2C3=CC(F)=CC=2)C3=N1 QKMNPUHPWJFRFL-UHFFFAOYSA-N 0.000 description 3
- DSKPZHRMHYDUHZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 DSKPZHRMHYDUHZ-UHFFFAOYSA-N 0.000 description 3
- YIEYSFIVIUQNBF-UHFFFAOYSA-N 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 YIEYSFIVIUQNBF-UHFFFAOYSA-N 0.000 description 3
- XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical compound NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940005530 anxiolytics Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OQTSXIJQJPCVIU-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(F)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C(Cl)=C1 OQTSXIJQJPCVIU-UHFFFAOYSA-N 0.000 description 2
- PTHZTNTXODWBHO-UHFFFAOYSA-N 2-(4-bromophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2)C3=N1 PTHZTNTXODWBHO-UHFFFAOYSA-N 0.000 description 2
- CDXGDOAOYZJBAQ-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(F)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C=C1 CDXGDOAOYZJBAQ-UHFFFAOYSA-N 0.000 description 2
- NGTOQMBNKLHRJA-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 NGTOQMBNKLHRJA-UHFFFAOYSA-N 0.000 description 2
- HYICCTJUXYNMNK-UHFFFAOYSA-N 4,4a,5,6-tetrahydro-2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NNC(=O)CC21 HYICCTJUXYNMNK-UHFFFAOYSA-N 0.000 description 2
- VSDILCSZFNGZRF-UHFFFAOYSA-N 8-chloro-2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2Cl)C3=N1 VSDILCSZFNGZRF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 2
- 229960002456 hexobarbital Drugs 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FRAKPAVZKUGWSR-UHFFFAOYSA-M sodium;bromite;trihydrate Chemical compound O.O.O.[Na+].[O-]Br=O FRAKPAVZKUGWSR-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- CRRIAWUJYMLJOE-UHFFFAOYSA-N (3-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(Cl)=C1 CRRIAWUJYMLJOE-UHFFFAOYSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- YQVZREHUWCCHHX-UHFFFAOYSA-N (4-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Cl)C=C1 YQVZREHUWCCHHX-UHFFFAOYSA-N 0.000 description 1
- HMHWNJGOHUYVMD-UHFFFAOYSA-N (4-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=C(NN)C=C1 HMHWNJGOHUYVMD-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- YZQAOIUQEJUTCP-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC(Cl)=CC=2)C3=N1 YZQAOIUQEJUTCP-UHFFFAOYSA-N 0.000 description 1
- QTUADMKLXGUNBO-UHFFFAOYSA-N 10-fluoro-2-(4-fluorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC(F)=CC=2)C3=N1 QTUADMKLXGUNBO-UHFFFAOYSA-N 0.000 description 1
- IILBZRVUJYTNNV-UHFFFAOYSA-N 10-fluoro-7-oxo-2-[3-(trifluoromethyl)phenyl]-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(F)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=CC(C(F)(F)F)=C1 IILBZRVUJYTNNV-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- AYJPYHRSFOISQA-UHFFFAOYSA-N 2-(2-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound ClC1=CC=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 AYJPYHRSFOISQA-UHFFFAOYSA-N 0.000 description 1
- NAVGADCTWBNCPQ-UHFFFAOYSA-N 2-(3-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound ClC1=CC=CC(N2C(CC3C(C4=CC=CC=C4SCC3)=N2)=O)=C1 NAVGADCTWBNCPQ-UHFFFAOYSA-N 0.000 description 1
- TYANXHYCUFWXFG-UHFFFAOYSA-N 2-(4-bromophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 TYANXHYCUFWXFG-UHFFFAOYSA-N 0.000 description 1
- WXVRWFDYIKCQMT-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-fluoro-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(F)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=C(Cl)C=C1 WXVRWFDYIKCQMT-UHFFFAOYSA-N 0.000 description 1
- VIFGKSBYGOOBBG-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-methyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(C)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C=C1 VIFGKSBYGOOBBG-UHFFFAOYSA-N 0.000 description 1
- SGMXTPJHXVMMHD-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-methyl-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(C)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=C(Cl)C=C1 SGMXTPJHXVMMHD-UHFFFAOYSA-N 0.000 description 1
- VWUGYIRMRAOOAG-UHFFFAOYSA-N 2-(4-chlorophenyl)-7-oxo-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCS(=O)C=2C3=CC=CC=2)C3=N1 VWUGYIRMRAOOAG-UHFFFAOYSA-N 0.000 description 1
- LPMSNKWSTXKGGR-UHFFFAOYSA-N 2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 LPMSNKWSTXKGGR-UHFFFAOYSA-N 0.000 description 1
- LCPUGWKGOOTDCC-UHFFFAOYSA-N 2-(4-fluorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2)C3=N1 LCPUGWKGOOTDCC-UHFFFAOYSA-N 0.000 description 1
- RQCPOXFVJUSNRL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 RQCPOXFVJUSNRL-UHFFFAOYSA-N 0.000 description 1
- KSUYUISXWPQBCX-UHFFFAOYSA-N 2-(5-oxo-3,4-dihydro-2h-1-benzothiepin-4-yl)acetic acid Chemical compound O=C1C(CC(=O)O)CCSC2=CC=CC=C21 KSUYUISXWPQBCX-UHFFFAOYSA-N 0.000 description 1
- KFGLLNVFBQRVQR-UHFFFAOYSA-N 2-(9-chloro-5-oxo-3,4-dihydro-2h-1-benzothiepin-4-yl)acetic acid Chemical compound O=C1C(CC(=O)O)CCSC2=C(Cl)C=CC=C21 KFGLLNVFBQRVQR-UHFFFAOYSA-N 0.000 description 1
- ADODRSVGNHNKAT-UHFFFAOYSA-N 2-Chlorophenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1Cl ADODRSVGNHNKAT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GQHVSNJPEAPQHK-UHFFFAOYSA-N 2-benzyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound O=C1C=C2CCSC3=CC=CC=C3C2=NN1CC1=CC=CC=C1 GQHVSNJPEAPQHK-UHFFFAOYSA-N 0.000 description 1
- JSGGKGHSDAQYJP-UHFFFAOYSA-N 2-butyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NN(CCCC)C(=O)C=C12 JSGGKGHSDAQYJP-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UPAXNLWDRLUQEA-UHFFFAOYSA-N 2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CSC2=CC=CC=C2C2=NNC(=O)C=C21 UPAXNLWDRLUQEA-UHFFFAOYSA-N 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KTPVHXCBYGDRPK-UHFFFAOYSA-N 5,6-dihydro-2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NNC(=O)C=C21 KTPVHXCBYGDRPK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OBYBYNYGRYGJMO-UHFFFAOYSA-N 8-chloro-2-(4-chlorophenyl)-7,7-dioxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)(=O)C=2C3=CC=CC=2Cl)C3=N1 OBYBYNYGRYGJMO-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000007107 Gatterman reaction Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- FNKJECMULJNDHK-UHFFFAOYSA-N [1]benzothiepino[5,4-c]pyridazine Chemical class S1C=CC2=CC=NN=C2C2=CC=CC=C12 FNKJECMULJNDHK-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001253 anti-conflict Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IYGYMKDQCDOMRE-ZWKOTPCHSA-N bicuculline Chemical compound O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-ZWKOTPCHSA-N 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000001206 effect on leukocytes Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63048464A JPH01250383A (ja) | 1987-03-02 | 1988-03-01 | ベンゾチエピノ〔5,4−c〕ピリダジン化合物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4849787 | 1987-03-02 | ||
JP62-48497 | 1987-03-02 | ||
JP62-172469 | 1987-07-09 | ||
JP62-306227 | 1987-12-02 | ||
JP63048464A JPH01250383A (ja) | 1987-03-02 | 1988-03-01 | ベンゾチエピノ〔5,4−c〕ピリダジン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01250383A JPH01250383A (ja) | 1989-10-05 |
JPH0555509B2 true JPH0555509B2 (pt) | 1993-08-17 |
Family
ID=26388741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63048464A Granted JPH01250383A (ja) | 1987-03-02 | 1988-03-01 | ベンゾチエピノ〔5,4−c〕ピリダジン化合物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01250383A (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597918A (en) * | 1991-08-27 | 1997-01-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyridazine compound |
CA2116448A1 (en) * | 1991-08-27 | 1993-03-04 | Tohru Nakao | Fused pyridazine compound and pharmaceutical use thereof |
-
1988
- 1988-03-01 JP JP63048464A patent/JPH01250383A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH01250383A (ja) | 1989-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6483697B2 (ja) | Tnf活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体 | |
DE69936998T2 (de) | Pyrazolotriazinderivate als gaba-rezeptorliganden | |
US20040127492A1 (en) | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | |
DE69637369T2 (de) | Trizyclische Benzazepin-Vasopressin-Antagonisten | |
US4613603A (en) | Compounds with a nitrogen-containing heterocyclic nucleus, and drugs in which they are present | |
DE69630209T2 (de) | Bicyclische benzazepin-derivate als vasopressin-antagonisten | |
CZ290883B6 (cs) | Triazolopyridazinové deriváty, způsob jejich výroby a farmaceutický prostředek je obsahující | |
WO1996022295A9 (en) | Tricyclic benzazepine vasopressin antagonists | |
JP2003516989A (ja) | Gaba受容体リガンドとしてのピラゾロ−ピリジン誘導体 | |
US5514687A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and method of use | |
JPH1179996A (ja) | キナゾリン−4−オンampaアンタゴニスト | |
JPH0565288A (ja) | 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物 | |
KR900006756B1 (ko) | 벤조티에피노[5,4-c]피리다진 화합물 및 그의 약학적 용도 | |
JP2002509150A (ja) | Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体 | |
US4965264A (en) | Thienocinnoline compounds and their pharmaceutical use | |
DE69907923T2 (de) | Triazolopyridazinderivate zur verbesserung der kognitiven funktionen | |
JPH0555509B2 (pt) | ||
WO1990003380A1 (en) | Thienocycloheptapyridazine compounds and medicinal uses thereof | |
JP2969911B2 (ja) | チオフェン化合物、その医薬用途およびその合成中間体 | |
JP2002536449A (ja) | Gabaレセプターに対するリガンドとしてのトリアゾロ−ピリダジン誘導体 | |
DE60005349T2 (de) | Dithiepino[6,5-b]pyridine und diese verwendete zusamensetzungen und methode | |
JP2003514909A (ja) | 認識能力増強用ピラゾロ〔1,5−d〕〔1,2,4〕トリアジン | |
JP2615785B2 (ja) | チエノシンノリン化合物 | |
US4983603A (en) | Tricyclic cholinergic receptor agonists | |
JP2531687B2 (ja) | ベンズオキセピノ〔5,4−c〕ピリダジン化合物 |